Darzalex® is not chemotherapy. Darzalex® is a monoclonal antibody that works in several ways. One way this monoclonal antibody works is by attaching itself to multiple myeloma cells in your body and directly killing them, and/or allowing your immune system to destroy them.
Darzalex® targets and attaches to a protein called CD38, which is present on the surface of certain types of cells (eg, red blood cells) and is also present in high numbers on multiple myeloma cells. Since Darzalex® targets the CD38 protein, it may also affect other cells with this protein on their surface.
SparkCures ID | 51 |
---|---|
Developed By | Janssen Research & Development |
Brand Name | Darzalex® |
Generic Name | Daratumumab |
Additional Names | CD38 mAb, HuMax-CD38 |
Treatment Classifications | |
Treatment Targets | |
Tags |
|
View all active clinical trials around the US.
SparkCures Verified Accurate, up-to-date information. Learn more
The following is a listing of clinical trials for patients with multiple myeloma who have been newly diagnosed or have not yet received treatment.
SparkCures Verified Accurate, up-to-date information. Learn more
The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.
SparkCures Verified Accurate, up-to-date information. Learn more
The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.
The following is a listing of clinical trials for patients with Smoldering Myeloma.
December 16, 2017